Replimune Group (NASDAQ:REPL) Hits New 52-Week High - Still a Buy?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) reached a new 52-week high on Monday . The company traded as high as $12.97 and last traded at $12.54, with a volume of 41626 shares. The stock had previously closed at $12.44.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. JPMorgan Chase & Co. upped their price target on Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, September 24th. Roth Mkm started coverage on Replimune Group in a report on Tuesday, August 27th. They set a "buy" rating and a $17.00 price objective on the stock. Roth Capital raised Replimune Group to a "strong-buy" rating in a report on Tuesday, August 27th. Finally, HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Replimune Group in a research report on Monday, September 16th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $16.80.

Replimune Group Price Performance

The firm has a market cap of $854 million, a PE ratio of -3.82 and a beta of 1.19. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. The business has a fifty day moving average of $11.33 and a 200-day moving average of $9.40.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.10. As a group, research analysts predict that Replimune Group, Inc. will post -3.05 earnings per share for the current year.

Insider Activity

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the business's stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now directly owns 101,057 shares of the company's stock, valued at $1,028,760.26. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 8.80% of the company's stock.

Institutional Investors Weigh In On Replimune Group

Several hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC grew its stake in shares of Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company's stock worth $45,000 after acquiring an additional 4,946 shares in the last quarter. Point72 DIFC Ltd purchased a new position in shares of Replimune Group during the 2nd quarter worth approximately $57,000. Arizona State Retirement System acquired a new stake in Replimune Group during the second quarter worth approximately $108,000. Quest Partners LLC boosted its holdings in shares of Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company's stock valued at $122,000 after purchasing an additional 3,150 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in shares of Replimune Group in the 1st quarter valued at $140,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.